Clinical trials: Tumor Pancreas
Pancreas Cancer
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
Researchers want to discover if the new drug "TG01" will work with participants' bodies to help their immune system attack any cancer cells that might still be in the blood stream after surgery for pancreatic cancer.
- Trial name
- TESLA (NCT05638698)
- Testing
- TG01 Vaccine, QS-21, Balstilimab
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Kansas Medical Center
Pancreatic Cancer
Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air
Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm.
- Trial name
- NCT01994681
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rauscher, Gregory E., M.D. PA
Liver Cancer, Anxiety Disorder
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are…
- Conditions
- Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer
- Trial name
- NCT02349412
- Testing
- Early palliative care
- Where
- 23 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00550836
- Testing
- panitumumab, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 262 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Unresectable Pancreatic Adenocarcinoma
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Trial name
- CA209-9KH (NCT04098432)
- Testing
- Nivolumab, Stereotactic radiotherapy
- Where
- 4 sites in Czechia
- Volunteers
- 15 people
- Sponsor
- University Hospital Hradec Kralove
Breast Cancer, Lung Cancer
Pillars4Life Trial
This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving…
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer
- Trial name
- Pillars4Life (NCT02465892)
- Testing
- Pillars4Life
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- Duke University
Pancreatectomy
Psychological Effect of the pancréatectomy: a Feeling of Strangeness
The cancer of the pancreas represents 1,8 % of cancers in France, with 9040 new cases in 2011 (France). This cancer is known to be of dark forecast.
- Trial name
- REPPSE (NCT03686592)
- Testing
- Measurement of body awareness
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Institut Paoli-Calmettes
Resectable Pancreatic Cancer
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
This is a phase II multi-center study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients.
- Trial name
- NCT03392571
- Testing
- NGC-Triple regimen
- Sponsor
- Pancreatic Cancer Research Team
Pancreas Cancer
Less Than 100 Hours Hospital Stay After Pancreatico-duodenectomy, RCT
Few decades back pancreatico-duodenectomy (PD) was associated with a very high morbidity and mortality. With recent advancements in surgical and anesthetic techniques and improvement in peri-operative care, PD has evolved into a…
- Trial name
- NCT05192044
- Testing
- Fast track Care pancreatico-duodenectomy., Conventional Care
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute, Egypt
Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
This is a prospective, single-center, randomized, controlled phase Ⅲ study.
- Trial name
- NCT04617821
- Testing
- Nab paclitaxel plus gemcitabine, mFOLFIRINOX
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Pancreatic Cancer
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and gemcitabine in subjects with previously untreated and unresectable pancreatic cancer.
- Trial name
- NCT01167816
- Testing
- Vidaza
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer
GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
Single-arm, prospective, phase II study to evaluate safety and activity of an induction therapy with Gemcitabine (GEM) and nab-paclitaxel plus Losartan followed by Stereotactic Radiotherapy (SBRT) in patients affected by Locally…
- Trial name
- OVERPASS (NCT05861336)
- Testing
- Losartan, Gemcitabine, Nab paclitaxel
- Where
- 2 sites in Italy
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Pancreatic Adenocarcinoma
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT02749136
- Testing
- Preoperative modified FOLFIRINOX and postoperative gemcitabine
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Resectable Pancreatic Cancer
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if…
- Trial name
- CIRCPAC (NCT05788744)
- Testing
- ctDNA
- Where
- 5 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- Copenhagen University Hospital at Herlev
Malignant Melanoma, Pancreatic Cancer
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
This study evaluates the safety, the immunological response and the clinical outcome of a vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and cervical carcinoma.
- Conditions
- Malignant Melanoma, Pancreatic Cancer, Colon Cancer, Cervical Cancer
- Trial name
- NCT00108875
- Testing
- Survivin peptide vaccine
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Julius-Maximilians University
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
- Trial name
- PRISM-1 (NCT06608927)
- Testing
- Quemliclustat, Nab-paclitaxel, Gemcitabine
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 610 people
- Sponsor
- Arcus Biosciences, Inc.
Carcinoma
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany.
- Trial name
- NCT02303353
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- SPGO Research Mannheim GmbH
Cancer, Pancreatic Cancer
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain…
- Trial name
- PanGen (NCT02869802)
- Testing
- Tumour Biopsy, Serial Collection of Plasma and Serum Samples
- Where
- 4 sites in Canada
- Volunteers
- 190 people
- Sponsor
- British Columbia Cancer Agency
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.